Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31298039 | 0.98 | HSD17B10 (0.57) | HSD17B10HRH3CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL5574053 | 0.91 | HSD17B10 (0.47) | HSD17B10HRH3SIGMAR1 | |
| SCHEMBL13632361 | 0.82 | HSD17B10 (0.46) | HSD17B10 | |
| SCHEMBL4023110 | 0.80 | HSD17B10 (0.42) | HSD17B10HRH3SIGMAR1 | |
| SCHEMBL7092659 | 0.78 | HSD17B10 (0.41) | HSD17B10HRH3ALDH1A1SIGMAR1 | |
| SCHEMBL4024810 | 0.78 | HSD17B10 (0.41) | HSD17B10HRH3ALDH1A1SIGMAR1 | |
| SCHEMBL1306555 | 0.78 | HSD17B10 (0.46) | HSD17B10HRH3CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL4915224 | 0.78 | GNAI3 (0.44) | HSD17B10SIGMAR1 | |
| SCHEMBL23828672 | 0.78 | HRH3 (0.81) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL17525461 | 0.78 | HRH3 (0.71) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | HSD17B10 2583/4885HRH3 3787/4885CYP1A2 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.